Cancer Network

4 days ago | cancernetwork.com | Ariana Pelosci

Elranatamab-bcmm (Elrexfio) plus daratumumab (Darzalex) and lenalidomide (Revlimid; EDR) is safe and manageable for patients with transplant-ineligible multiple myeloma, according to results from the phase 3 MagnetisMM-6 Part 1 dose level G trial (NCT05623020), presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

4 days ago | cancernetwork.com | Kristi Rosa

A statistically significant and clinically meaningful overall survival (OS) benefit was observed when neoadjuvant novolumab (Opdivo) plus chemotherapy vs chemotherapy alone was used to treat patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

4 days ago | cancernetwork.com | Ariana Pelosci

Patients with medium to high locally advanced rectal cancer who received short-course radiotherapy (SCRT) followed by 1 cycle of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and 7 cycles of folinic acid, 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) had improved activity, according to results from the single-arm phase 2 ShorTrip trial (NCT05253846) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 days ago | cancernetwork.com | Ariana Pelosci

Patients with metastatic castration-resistant prostate cancer (mCRPC) experienced a response with nivolumab (Opdivo) plus ipilimumab (Yervoy); however, the addition of stereotactic body radiation therapy (SBRT) was found to be safe but did not improve efficacy, according to results from the phase 2 CheckPRO trial (NCT05655715) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 days ago | cancernetwork.com | Kristi Rosa

Progression-free survival (PFS) and overall survival (OS) improved among subgroups of patients with relapsed/refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel; Carvykti), according to subgroup analysis findings from the phase 3 CARTITUDE-4 study (NCT04181827) presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Data showed that in those with high-risk cytogenetics—defined as del(17p), t(4;14), t(14;16), or...